However, the following studies have found that LOXL2 was highly expressed in breast cancer, colorectal cancer, esophageal cancer, bile duct cancer, liver cancer, pancreatic cancer and gastric cancer, and was closely associated with metastasis and prognosis16-19. Here, LOXL2 is linked to breast carcinoma.